KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Profit After Tax: 2013-2025

Historic Profit After Tax for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Profit After Tax fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$306.3 million, marking a year-over-year decrease of 43.56%. This contributed to the annual value of -$234.3 million for FY2024, which is 28.48% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Profit After Tax stood at -$90.9 million for Q3 2025, which was down 7.31% from -$84.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Profit After Tax high stood at -$15.4 million for Q3 2021, and its period low was -$90.9 million during Q3 2025.
  • For the 3-year period, Xenon Pharmaceuticals' Profit After Tax averaged around -$59.8 million, with its median value being -$57.9 million (2024).
  • Data for Xenon Pharmaceuticals' Profit After Tax shows a maximum YoY plummeted of 12,533.71% (in 2021) over the last 5 years.
  • Xenon Pharmaceuticals' Profit After Tax (Quarterly) stood at -$25.6 million in 2021, then crashed by 46.28% to -$37.4 million in 2022, then fell by 19.65% to -$44.7 million in 2023, then crashed by 46.81% to -$65.7 million in 2024, then crashed by 44.76% to -$90.9 million in 2025.
  • Its last three reported values are -$90.9 million in Q3 2025, -$84.7 million for Q2 2025, and -$65.0 million during Q1 2025.